LEADING ARTICLE
REVIEWS AND LECTURES
Homocysteine (Hcy) is sulfurcontaining aminoacide and its high level (hyperhomocysteinemia, HHcy) is a predictor of unfavorable event of diseases. Biochemical bases of influence of HHcy to the development and progression of chronic renal disease and cardiovascular complications are discussed in this review. Correction ways of HHcy are presented.

ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS
Osteocalcin is a vitamin K-dependent protein secreted by osteoblasts. In vitamin K deficiency the fraction of the inactive, undercarboxylated osteocalcin (ucOC) is increased. Chronic kidney disease is associated with bone loss and there is evidence for a sub-optimal status of vitamin K in renal patients. THE AIM of the present study was to assess the vitamin K status in postmenopausal hemodialysis patients based on their ucOC level with the background idea to substantiate the need of vitamin K supplementation. PATIENTS AND METHODS. 78 postmenopause women were divided into 3 groups: 1) women on hemodialysis; 2) a control group with normal bone mineral density; 3) osteoporosis group. Serum ucOC was measured immunochemically. Osteoporosis was verified by DEXA scan of the radius. RESULTS. Serum ucOC in hemodialysis women was significantly increased in comparison with control and osteoporosis group, which did not differ significantly between each other. In hemodialysis patients, a strong positive correlation was found between ucOC and parathormone and between ucOC and hemodialysis duration. CONCLUSION. The increase of ucOC in hemodialysis postmenopausal patients may indicate a severe vitamin K deficit, but other factors may also contribute. Therefore, additional investigation is needed to justify supplementation with vitamin K in these patients.

THE AIM of the research was investigation of Prostagut-forte phytogenic drug efficiency in treatment of BPH patients. PATIENTS AND METHODS. Treatment was provided for 86 patients with BPH, clinically manifested by symptoms of lower urinary tract. All patients were assigned 1 capsule of prostagut-forte (280 mg) 2 times a day during 6 months as monotherapy. RESULTS. Obtained data shown efficiency of prostagut-forte usage at patients with BPH. 68 patients (79,1%) at the end of treatments 1 month pointed out symptomatology improving. In quoted period score decreasing on I-PSS scale compounds accordingly - 31,9%,-38,6% and -41%. The subjective improvement accompanied by increasing of measurements characterising urine outflow from urinary bladder. Maximal urine flow speed average increased on +30,8% and residual urine volume decreased on -48,4% to the end of treatment. Evidential prostate size and PSA level alteration is not noticed during treatment. Most quick effect was noticed at first therapy month. CONCLUSION. Provided research approved that prostagut-forte prescription inspires clinical BPH appearances intensity decreasing. Prostagut-forte therapeutic action based on occurrence antiandrogenic, anti-inflammatory and immunomodulatory effect in preparation. Application during treatment of patients with BPH may consider pathogenetic reasonably, as long as it influences on basic disease pathogenesis component.

KDIGO PAGE
DISCUSSION AND INFORMATION
ISSN 2541-9439 (Online)